PTAB Finds Two Abbvie Adalimumab Method of Use Patents Unpatentable in Final Written Decisions

PTAB + IPR

The PTAB has issued Final Written Decisions in IPRs filed by Coherus against two of Abbvie’s patents, IPR2016-00188 (U.S. Patent No. 9,017,680) and IPR2016-00189 (U.S. Patent No. 9.073,987), finding the challenged claims unpatentable as obvious over the prior art.  The patents are directed to methods of treating rheumatoid arthritis using adalimumab.  Adalimumab is marketed by Abbvie under the trade-name Humira®.

These decisions and other selected IPR documents regarding biologics are posted on our IPR tracker page.

Download PDF

Tagged with 

Comments are closed.